Ikarian Capital 13F annual report
Ikarian Capital is an investment fund managing more than $320 billion ran by Troy Wuertz. There are currently 85 companies in Mr. Wuertz’s portfolio. The largest investments include Sarepta Therapeutics Inc and Crinetics Pharmaceuticals In, together worth $58.5 billion.
$320 billion Assets Under Management (AUM)
As of 7th August 2024, Ikarian Capital’s top holding is 203,612 shares of Sarepta Therapeutics Inc currently worth over $32.2 billion and making up 10.0% of the portfolio value.
Relative to the number of outstanding shares of Sarepta Therapeutics Inc, Ikarian Capital owns more than approximately 0.1% of the company.
In addition, the fund holds 588,818 shares of Crinetics Pharmaceuticals In worth $26.4 billion.
The third-largest holding is Tarsus Pharmaceuticals worth $21.8 billion and the next is Soleno Therapeutics Inc worth $18.2 billion, with 445,451 shares owned.
Currently, Ikarian Capital's portfolio is worth at least $320 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Ikarian Capital
The Ikarian Capital office and employees reside in Dallas, Texas. According to the last 13-F report filed with the SEC, Troy Wuertz serves as the CHIEF COMPLIANCE OFFICER at Ikarian Capital.
Recent trades
In the most recent 13F filing, Ikarian Capital revealed that it had opened a new position in
Enliven Therapeutics Inc and bought 586,552 shares worth $13.7 billion.
The investment fund also strengthened its position in Sarepta Therapeutics Inc by buying
51,334 additional shares.
This makes their stake in Sarepta Therapeutics Inc total 203,612 shares worth $32.2 billion.
Sarepta Therapeutics Inc soared 18.7% in the past year.
On the other hand, there are companies that Ikarian Capital is getting rid of from its portfolio.
Ikarian Capital closed its position in Alpine Immune Sciences Inc on 14th August 2024.
It sold the previously owned 261,365 shares for $10.4 billion.
Troy Wuertz also disclosed a decreased stake in Crinetics Pharmaceuticals In by approximately 0.1%.
This leaves the value of the investment at $26.4 billion and 588,818 shares.
One of the smaller hedge funds
The two most similar investment funds to Ikarian Capital are High Note Wealth and Van Den Berg Management I, Inc. They manage $321 billion and $321 billion respectively.
Troy Wuertz investment strategy
Ikarian Capital’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 58.0% of
the total portfolio value.
The fund focuses on investments in the United States as
44.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
13% of the total holdings value.
On the other hand, large-cap stocks make up only 3.5% of the portfolio.
The average market cap of the portfolio companies is close to $4.71 billion.
The complete list of Ikarian Capital trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Sarepta Therapeutics Inc |
33.71%
203,612
|
$32,170,696,000 | 10.04% |
| Crinetics Pharmaceuticals In |
8.53%
588,818
|
$26,373,158,000 | 8.23% |
| Tarsus Pharmaceuticals, Inc. |
12.67%
800,277
|
$21,751,529,000 | 6.79% |
| Soleno Therapeutics Inc |
21.22%
445,451
|
$18,174,401,000 | 5.67% |
| Corbus Pharmaceuticals Hldgs |
44.65%
309,540
|
$14,006,685,000 | 4.37% |
| Enliven Therapeutics Inc |
Opened
586,552
|
$13,707,720,000 | 4.28% |
| AMGEN Inc. |
Opened
38,300
|
$11,966,835,000 | 3.73% |
| Nuvalent Inc |
49.21%
151,601
|
$11,500,452,000 | 3.59% |
| Alpine Immune Sciences Inc |
Closed
261,365
|
$10,360,508,000 | |
| Praxis Precision Medicines I |
Closed
168,388
|
$10,275,036,000 | |
| Cytokinetics Inc |
17.22%
170,147
|
$9,218,564,000 | 2.88% |
| Nurix Therapeutics, Inc. |
46.83%
440,500
|
$9,193,234,000 | 2.87% |
| BridgeBio Pharma Inc |
17.73%
332,013
|
$8,409,889,000 | 2.62% |
| Catalyst Pharmaceuticals Inc |
No change
518,386
|
$8,029,799,000 | 2.51% |
| Alnylam Pharmaceuticals Inc |
Closed
51,541
|
$7,702,802,000 | |
| Viking Therapeutics Inc |
Opened
138,262
|
$7,329,269,000 | 2.29% |
| Immunovant Inc |
No change
276,925
|
$7,310,821,000 | 2.28% |
| Cartesian Therapeutics Inc |
Opened
242,370
|
$6,546,413,000 | 2.04% |
| Acelyrin Inc |
5.71%
1,475,074
|
$6,505,077,000 | 2.03% |
| Neurocrine Biosciences, Inc. |
Opened
40,000
|
$5,506,799,000 | 1.72% |
| Pyxis Oncology Inc |
No change
1,662,408
|
$5,502,571,000 | 1.72% |
| BiomX Inc |
Closed
10,817,327
|
$4,867,797,000 | |
| Arcutis Biotherapeutics Inc |
16.96%
489,642
|
$4,553,672,000 | 1.42% |
| Rocket Pharmaceuticals Inc |
33.66%
197,096
|
$4,243,477,000 | 1.32% |
| Xenon Pharmaceuticals Inc |
No change
107,187
|
$4,179,221,000 | 1.30% |
| Cervomed Inc |
No change
237,345
|
$4,063,346,000 | 1.27% |
| Rezolute Inc |
Opened
903,744
|
$3,886,099,000 | 1.21% |
| Cybin Inc |
No change
13,953,488
|
$3,781,396,000 | 1.18% |
| Lenz Therapeutics Inc |
140.60%
204,513
|
$3,536,029,000 | 1.10% |
| Silence Therapeutics plc |
Opened
506,665
|
$3,293,324,000 | 1.03% |
| Inhibrx Biosciences Inc |
Opened
230,000
|
$3,259,099,000 | 1.02% |
| Abeona Therapeutics Inc |
13.50%
768,593
|
$3,258,835,000 | 1.02% |
| Insmed Inc |
6.82%
47,835
|
$3,204,945,000 | 1.00% |
| Terns Pharmaceuticals Inc |
418.09%
458,497
|
$3,122,365,000 | 0.97% |
| Verona Pharma Plc |
46.41%
201,116
|
$2,908,138,000 | 0.91% |
| Wave Life Sciences Ltd. |
2.54%
575,088
|
$2,869,690,000 | 0.90% |
| Uniqure Nv |
Closed
469,133
|
$2,439,492,000 | |
| Jasper Therapeutics Inc |
No change
105,175
|
$2,387,473,000 | 0.74% |
| Larimar Therapeutics, Inc. |
26.22%
323,528
|
$2,345,578,000 | 0.73% |
| Arcus Biosciences Inc |
Opened
145,000
|
$2,208,350,000 | 0.69% |
| Apellis Pharmaceuticals Inc |
Closed
35,092
|
$2,062,708,000 | |
| Astria Therapeutics Inc |
Closed
140,687
|
$1,980,170,000 | |
| Q32 Bio Inc |
388.44%
109,094
|
$1,958,237,000 | 0.61% |
| Elevation Oncology Inc |
366.00%
690,089
|
$1,863,242,000 | 0.58% |
| Annexon Inc |
72.95%
380,000
|
$1,862,000,000 | 0.58% |
| COMPASS Pathways plc |
Opened
302,908
|
$1,829,564,000 | 0.57% |
| Nektar Therapeutics |
Opened
1,312,405
|
$1,627,382,000 | 0.51% |
| Disc Medicine Inc |
Closed
25,372
|
$1,579,660,000 | |
| Scholar Rock Hldg Corp |
37.02%
183,701
|
$1,530,229,000 | 0.48% |
| Sagimet Biosciences Inc |
No change
412,565
|
$1,410,973,000 | 0.44% |
| Tourmaline Bio Inc |
No change
108,483
|
$1,395,092,000 | 0.44% |
| iBio Inc |
No change
600,000
|
$1,266,000,000 | 0.40% |
| Inflarx Nv |
No change
704,987
|
$1,226,677,000 | 0.38% |
| Achilles Therapeutics Plc |
No change
1,443,181
|
$1,176,193,000 | 0.37% |
| Mind Medicine Mindmed Inc |
45.38%
162,481
|
$1,171,487,000 | 0.37% |
| iTeos Therapeutics, Inc. |
22.45%
78,574
|
$1,166,038,000 | 0.36% |
| Kodiak Sciences Inc |
No change
476,586
|
$1,119,977,000 | 0.35% |
| Roivant Sciences Ltd |
No change
100,609
|
$1,063,437,000 | 0.33% |
| Nuvation Bio Inc |
43.42%
358,282
|
$1,046,183,000 | 0.33% |
| Tectonic Therapeutic Inc |
Opened
62,836
|
$1,034,909,000 | 0.32% |
| Ventyx Biosciences Inc |
12.80%
442,647
|
$1,022,514,000 | 0.32% |
| Allakos Inc |
4.29%
972,675
|
$972,675,000 | 0.30% |
| AvroBio Inc |
Closed
754,061
|
$965,198,000 | |
| Macrogenics Inc |
37.12%
200,079
|
$850,337,000 | 0.27% |
| Delcath Sys Inc |
Opened
100,370
|
$840,097,000 | 0.26% |
| Marinus Pharmaceuticals Inc |
31.27%
706,154
|
$826,200,000 | 0.26% |
| Proqr Thrapeutics N V |
No change
483,583
|
$802,748,000 | 0.25% |
| Veru Inc |
No change
946,382
|
$796,191,000 | 0.25% |
| Lyell Immunopharma Inc |
Opened
526,066
|
$762,796,000 | 0.24% |
| Eliem Therapeutics Inc |
Opened
100,000
|
$711,001,000 | 0.22% |
| Avalo Therapeutics Inc |
97.26%
54,730
|
$682,483,000 | 0.21% |
| Acumen Pharmaceuticals Inc |
No change
266,435
|
$644,774,000 | 0.20% |
| Milestone Pharmaceuticals In |
No change
466,019
|
$619,806,000 | 0.19% |
| Aerovate Therapeutics Inc |
No change
367,965
|
$610,822,000 | 0.19% |
| Immatics N.v |
No change
49,415
|
$574,202,000 | 0.18% |
| Immunic, Inc. |
69.39%
493,496
|
$547,781,000 | 0.17% |
| Amylyx Pharmaceuticals Inc |
17.17%
274,551
|
$521,647,000 | 0.16% |
| Kezar Life Sciences Inc |
No change
868,992
|
$521,395,000 | 0.16% |
| RAPT Therapeutics, Inc. |
No change
154,625
|
$471,606,000 | 0.15% |
| Voyager Therapeutics Inc |
69.12%
55,857
|
$441,829,000 | 0.14% |
| Anebulo Pharmaceuticals Inc |
No change
157,862
|
$430,964,000 | 0.13% |
| Sensei Biotherapeutics Inc |
Opened
650,000
|
$403,065,000 | 0.13% |
| Hookipa Pharma Inc |
Closed
530,776
|
$377,913,000 | |
| Protara Therapeutics Inc |
10.85%
180,712
|
$375,881,000 | 0.12% |
| Nyxoah S A |
No change
50,699
|
$356,921,000 | 0.11% |
| Karyopharm Therapeutics Inc |
No change
409,355
|
$355,157,000 | 0.11% |
| Lyra Therapeutics, Inc. |
No change
1,056,829
|
$292,424,000 | 0.09% |
| Aeon Biopharma Inc |
No change
257,977
|
$270,876,000 | 0.08% |
| Tempest Therapeutics Inc |
No change
105,600
|
$231,264,000 | 0.07% |
| Chemomab Therapeutics Ltd |
No change
213,392
|
$196,320,000 | 0.06% |
| Relmada Therapeutics Inc |
No change
40,369
|
$121,107,000 | 0.04% |
| Stoke Therapeutics, Inc. |
No change
6,816
|
$92,083,000 | 0.03% |
| Synlogic Inc |
No change
20,448
|
$30,673,000 | 0.01% |
| Brainstorm Cell Therapeutics, Inc. |
No change
90,242
|
$30,547,000 | 0.01% |
| EyePoint Pharmaceuticals Inc |
Closed
1,047
|
$21,642,000 | |
| Finch Therapeutics Group Inc |
Closed
6,892
|
$18,126,000 | |
| CytomX Therapeutics Inc |
Opened
8,924
|
$10,887,000 | 0.00% |
| Tyra Biosciences Inc |
Closed
501
|
$8,216,000 | |
| ASLAN Pharmaceuticals Ltd |
Closed
35,420
|
$6,273,000 | |
| Longboard Pharmaceuticals In |
Closed
236
|
$5,098,000 | |
| No transactions found | |||
| Showing first 500 out of 100 holdings | |||
Hedge funds similar to Ikarian Capital
- Amj Wealth Management
- Watts Gwilliam & Co
- Hound Partners
- Dedora Capital
- Whitcomb & Hess
- Van Den Berg Management I, Inc
- High Note Wealth
- Geometric Wealth Advisors
- Boltwood Capital Management
- Kidder Stephen W
- Citizens & Northern Corp
- Svf Sponsor Iii (de)
- Kerrisdale Advisers
- Etf Portfolio Partners